


FORM PTO-4449 (REV. 7-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
 LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	AA	3	4	4	4	2	9	9	06/22/1976	Leslie	424	22		
	AB	4	2	3	2	4	4	4	12/02/1980	Dudzinski	424	260		
	AE	4	9	9	4	3	9	4	12/28/1982	Leslie	536	56		
	AD	4	4	4	3	4	2	4	04/17/1984	Oshlack, et al.	424	22		
	AE	4	9	2	9	9	9	4	05/30/1989	Elger, et al.	424	488		
	AF	4	6	3	4	6	6	5	05/30/1989	Martani, et al.	424	488		
	AE	4	9	9	4	9	9	4	05/30/1989	Goldie, et al.	424	488		
	AH	4	4	9	4	9	9	9	05/30/1989	Elger, et al.	424	488		
	AE	4	9	4	4	9	0	2	07/04/1989	Elger, et al.	424	488		
	AJ	4	9	4	4	9	0	9	07/04/1989	Goldie, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
										YES	NO			
	AK	0	1	9	9	9	9	9	09/03/1986	Europe (A3)	A61K	31/615		
	AE	0	4	4	9	2	4	4	06/07/1989	Europe (A1)	A61K	31/485		
	AM	4	3	9	9	2	4	4	11/07/1990	Europe (A2)	A61K	31/485		
	AW	0	0	0	9	3	7	7	01/13/2000	WO	A61K	31/00		
	AE	9	4	4	4	4	9	9	05/17/1990	WO	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	AE	Translation of previously submitted German patent application DE 43 25 465												
	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53, pg. 1201-1205												
	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52, pg. 659-663												
EXAMINER							/Humera Sheikh/				DATE CONSIDERED		08/01/2010	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.						
				FILING DATE: October 21, 2003		GROUP: 1615				
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	4	6	4	4	4	4	07/04/1989	Leslie, et al.	424 494
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
										YES NO
	BB									
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)										
	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9								
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429								
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83								
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5th National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349								
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213								
	BH	Briscoe, et al., "Methoclopramide: Time Course of Changes in Alentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399								
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551								
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343								
	BL	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Thera (1974) Vol. 15; No. 6 pg. 556-564								
	BH	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F 1973								
	BM	Cherny, Nathan L., "Opioid Analgesics"; Drugs (1996) May; 51 (5) pg. 713-737								
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8								
	BC	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708								
	BD	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159: pg. 351-360								
	BC	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280								
EXAMINER		/Humera Sheikh/				DATE CONSIDERED				
						08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	CA	8	8	8	7	6	8	5	09/19/1989	Heafeld, et al.	424	461	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	CB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11											
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131											
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577 1968											
	CF	Fishman, et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580											
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386											
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30											
	CC	Fudala, et al., "Effects of Buprenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8											
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306											
	CK	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542											
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41											
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113											
	CC	Giatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197											
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647											
	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting μ Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236											
EXAMINER						/Humera Sheikh/							
						DATE CONSIDERED 08/01/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA	4 0 0 0 5 5 7	07/10/1990	Jenkins, et al.	424	480	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	DB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39					
	DE	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arznei-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744					
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135					
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176					
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257					
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846					
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174					
	DI	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211					
	DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458					
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209					
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242					
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993					
	DE	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383					
	DE	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634					
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages					
	DR	Umbrecht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190					
EXAMINER /Humera Sheikh/				DATE CONSIDERED 08/01/2010			
EXAMINER: Initial reference considered whether or not citation is in conformance with MPEP 609. Drawings, if any, in conformance and not considered. Include copy of this form with next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /HS/							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	ED	7	0	7	7	0	7	5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	EB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034											
	ED	Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600											
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261 1976											
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342											
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid μ -Agonists/5-Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605											
	EF	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6											
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148											
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336											
	EI	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine produg controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209											
	EF	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445											
	EI	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94											
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630											
	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385											
EXAMINER						/Humera Sheikh/							
						DATE CONSIDERED							
						08/01/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003						
				GROUP: 1615								
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	FA	1	1	1	1	1	6	01/22/1991	Kreek, et al.	514	282	
	FB	1	5	4	6	3	4	02/05/1991	Goldie, et al.	424	468	
	FC	5	4	1	1	5	1	12/10/1991	Malikowska, et al.	424	468	
	FD	5	4	3	1	1	5	02/25/1992	Heafield, et al.	424	468	
	FE	5	1	1	5	2	5	06/01/1993	Krishnamurthy	424	468	
	FF	5	1	2	1	3	3	07/13/1993	Thompson, et al.	73	865.9	
	FC	5	2	1	5	3	3	11/30/1993	Oshlack, et al.	424	468	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
										YES	NO	
	FH											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	FK	Budd, Keith, "Clinical use of Opioid Antagonists", Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011										
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment", Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544										
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic", NIDA Research (1979) pg. 99-105										
	FL	Leeling, et al., "Disposition and metabolism of codorphine in the rat, dog and man", Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653										
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet", Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152										
	FD	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats", (1987) Vol 36, pg. 127-130										
	FM	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone", J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426										
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans", Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37										
	FQ	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects", J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pg. 355-363										
	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study", Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909										
EXAMINER							DATE CONSIDERED					
/Humera Sheikh/							08/01/2010					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Oshlack, et al. FILING DATE: October 21, 2003										
(Use several sheets if necessary)														
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	GA	5	2	2	2	4	9	3	02/15/1994	Oshlack, et al.	424	468		
	GF	5	3	2	0	8	8	1	06/28/1994	Oshlack, et al.	106	153		
	GC	5	3	3	5	6	9	2	08/09/1994	Raffa, et al.	514	629		
	GF	5	3	5	5	8	8	1	10/18/1994	Oshlack, et al.	106	468		
	GF	5	1	1	1	7	1	5	05/02/1995	Oshlack, et al.	424	468		
	GF	5	5	5	5	8	2	5	10/24/1995	Merrill, et al.	424	470		
	GC	5	1	1	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GH	1	1	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
	GF	5	1	3	2	1	8	5	05/10/2001	WO (A2)	A61K	31/485		
	GJ	0	8	8	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	GP	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34												
	GC	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
	GP	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pg. 1574 - 1577												
EXAMINER										DATE CONSIDERED				
/Humera Sheikh/										08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		GROUP: 1615							
				FILING DATE: October 21, 2003									
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	HA	5	6	7	6	5	7	7	12/26/1995	Sackler, et al.	424	468	
	HB	5	5	0	0	2	7	7	04/16/1996	Oshlack, et al.	424	476	
	HE	5	5	0	6	6	6	2	04/16/1996	Oshlack, et al.	424	468	
	HD	5	5	6	9	6	6	6	04/16/1996	Krishnamurthy	424	468	
	HE	5	5	0	6	6	1	2	08/27/1996	Oshlack, et al.	424	468	
	HF	5	5	5	2	0	2	2	09/03/1996	Gauthier, et al.	514	368	
	HE	5	5	6	1	6	5	7	01/07/1997	Miller, et al.	424	468	
	HA	5	6	6	1	9	9	5	02/11/1997	Buxton, et al.	424	468	
	HE	5	6	7	9	7	7	9	04/22/1997	Knott, et al.	424	468	
	HJ	5	6	9	9	9	7	9	06/17/1997	Oshlack, et al.	424	468	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	HK												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160											
	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneimittel-Forsch./Drug Res. (1999) Vol 49, pg. 599-607											
	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442											
	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46											
	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101											
	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 1973											
	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 1973											
EXAMINER /Humera Sheikh/						DATE CONSIDERED 08/01/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	IA	5	0	5	0	0	0	5	08/12/1997	Oshlack, et al.	424	468	
	IA	5	0	0	0	1	7	0	09/23/1997	Buxton, et al.	424	495	
	IF	5	0	7	0	0	0	0	09/30/1997	Sackler, et al.	424	490	
	ID	5	0	0	1	5	0	5	10/28/1997	Oshlack, et al.	424	494	
	IE	5	8	3	3	5	2		06/09/1998	Miller, et al.	514	282	
	IF	5	7	8	0	0	7	3	07/14/1998	Kim	514	282	
	IF	5	0	1	1	1	0	0	09/22/1998	Krishnamurthy	424	498	
	IE	5	8	3	3	3	2		11/10/1998	Mioduszewski	514	282	
	IF	5	8	0	0	0	0	0	12/01/1998	Miller, et al.	424	484	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	IE												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	IK	Parwatarikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence", Missouri Institute of Psychiatry, pg. 1350-1354 <u>1973</u>											
	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys", J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508											
	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490											
	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823											
	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34											
	IO	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149 <u>1997</u>											
	IO	Wikler, et al., "N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20											
EXAMINER /Humera Sheikh/									DATE CONSIDERED 08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JA	5 8 8 8 8 8 8 8	12/15/1998	Miller, et al.	264	456		
JB	5 8 8 8 8 8 8 8	02/09/1999	Wong, et al.	424	473		
JF	5 8 8 8 8 8 8 8	04/06/1999	Hcafield, et al.	424	464		
JD	5 8 8 8 8 8 8 8	04/06/1999	Miller, et al.	424	468		
JF	5 9 8 8 8 8 8 8	06/01/1999	Miller, et al.	514	282		
JF	5 5 5 8 8 8 8 8	09/28/1999	Oshlack, et al.	424	468		
JG	5 5 5 8 8 8 8 8	09/28/1999	Chasin, et al.	424	490		
JH	5 9 6 5 1 6 1 6	10/12/1999	Oshlack, et al.	424	464		
JF	5 9 6 5 8 8 8 8	10/12/1999	Miller, et al.	424	456		
JF	5 9 6 6 5 5 1 1	10/19/1999	Oshlack, et al.	424	456		
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
JK							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
JF	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110						
JF	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58						
JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213						
JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529						
JP	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258						
JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526						
JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217						
EXAMINER /Humera Sheikh/			DATE CONSIDERED 08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866											
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.													
				FILING DATE: October 21, 2003		GROUP: 1615											
U.S. PATENT DOCUMENTS																	
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
		1	2	3	4	5	6	7									
	KA	0	0	2	4	0	2	2	02/15/2000	Oshlack, et al.	424	449					
	KL	2	2	2	2	2	5	5	05/30/2000	Leslie, et al.	424	461					
	KC	2	2	7	2	6	2	2	06/20/2000	Malkowska, et al.	424	457					
	KD	6	6	7	7	6	6	6	06/20/2000	Oshlack, et al.	424	461					
	KC	6	1	2	2	2	5	2	02/15/2000	Simon	424	449					
	KF	9	9	2	2	2	9	1	09/25/2001	Chasin, et al.	424	459					
	KC	9	1	2	6	6	2	2	11/07/2000	Sackler, et al.	424	459					
	KH	9	1	2	3	6	2	2	11/07/2000	Heafield, et al.	424	457					
	KC	6	1	2	2	4	9	7	12/19/2000	Miller, et al.	424	449					
	KJ	9	2	9	2	7	9	2	04/03/2001	Oshlack, et al.	424	476					
	KK	6	2	6	4	2	6	7	07/03/2001	Miller, et al.	424	461					
	KF	9	2	9	9	9	9	9	07/17/2001	Oshlack, et al.	424	457					
	KM	9	2	9	2	1	2	5	09/25/2001	Oshlack, et al.	424	457					
FOREIGN PATENT DOCUMENTS																	
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
		1	2	3	4	5	6	7					YES	NO			
	KN	0	2	2	7	2	2	5	05/31/2001	WO (A2)	A61K						
	KD	2	1	6	2	2	6	1	09/25/2001	WO (A1)	A61K	31/485					
	KF	2	1	6	2	2	6	9	11/15/2001	WO (A2)	A61K						
	KD	2	1	9	9	2	5	2	12/19/2000	WO (A2)	A61K	31/00					
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)																	
	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans", Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82															
	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneimittel-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022															
EXAMINER										/Humera Sheikh/				DATE CONSIDERED			
														08/01/2010			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																	

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		LA	2	3	5	6	7	8					YES	NO
	LA	2	3	5	6	7	8	10/23/2001	Oshlack, et al.	424	468			
	LB	2	3	5	6	7	8	12/04/2001	Miller, et al.	424	468			
	LC	6	3	3	6	6	3	01/01/2002	Oshlack, et al.	424	480			
	LD	2	6	7	3	4	4	04/23/2002	Kaiko, et al.	424	400			
	LI	6	3	3	7	4	4	05/14/2002	Oshlack, et al.	424	480			
	LJ	6	6	4	6	6	4	01/01/2002	Miller, et al.	424	480			
	LJ	2	4	3	4	4	4	11/05/2002	Kaiko, et al.	424	400			
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO											
	LI													
	LI													
	LJ													
	LI													
	LC													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	LM													
	LN													
	LO													
	LP													
EXAMINER /Humera Sheikh/										DATE CONSIDERED 08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/699,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	MR 5 9 0 0 0 0 0 4	12/99	Mitch et al.	514	210.16		
	MB 5 9 0 2 0 0 0	10/99	Foss	514	282		
	MC 5 9 0 8 0 4 4	10/99	Reder et al.	424	449		
	MD 5 9 4 2 2 0 0	8/99	Chasin et al.	424	426		
	MJ 5 9 8 0 4 0 2	3/99	Hill	514	282		
	MF 5 9 0 0 0 0 4	2/99	Kuczynski et al.	424	472		
	MC 5 9 0 0 0 0 0	8/99	Demopoulos et al.	514	49		
	MI 5 9 0 0 0 0 0	1/99	Demopoulos et al.	514	890.1		
	MI 5 7 0 4 4 4 0	6/98	Crain et al.	514	282		
	MJ 5 9 0 5 2 5 5	5/97	Qin et al.	514	282		
	MR 5 9 2 0 0 0 2	4/97	Qin et al.	514	282		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	MJ 19 9 0 0 5 5 0	6/98	DE	A61K	31/485		
	MM 29 7 0 0 4 0 4	2/97	DE	A61K	31/485		
	MD 4 9 2 5 4 0 5	2/99	DE	A61K	31/485	X	
	MD 2 7 2 2 0 0 0	11/72	DE	A61K	27/00		
	MP 5 9 0 0 0 5 2	6/99	DE	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
MC	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.						
MR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.						
MS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.						
EXAMINER			DATE CONSIDERED				
/Humera Sheikh/			08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/669,866									
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003									
(Use several sheets if necessary)															
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	NK	5	5	1	0	0	0	1	2/98	Khanna et al.	514	399			
	NB	5	5	0	5	3	1	0	12/96	Crain et al.	514	12			
	NF	5	5	1	0	0	1	0	12/96	Crain et al.	514	282			
	ND	5	5	0	0	1	2	5	11/96	Portoghesi et al.	546	35			
	NF	5	5	1	0	0	1	2	11/96	Rose et al.	514	343			
	NF	5	5	5	0	0	0	0	9/96	Mayer et al.	514	25			
	NG	5	5	3	1	0	1	2	1/96	Aston et al.	514	608			
	NH	5	5	1	1	0	0	0	8/98	Weber et al.	514	249			
	NF	5	5	1	2	5	0	0	1/96	Crain et al.	514	282			
	NJ	0	0	0	2	0	0	1	9/96	Mayer et al.	514	289			
	NK	5	1	0	0	3	0	2	1/96	Kitchell et al.	424	426			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	NG	0	1	1	0	1	1	1	2/98	EP	A61K	31/485			
	NM	0	3	0	2	3	0	1	8/90	EP	A61K	31/485			
	NN	0	2	0	0	2	0	2	12/86	EP	A61K	9/22			
	ND	0	0	0	2	1	2	0	8/99	WO	A61K	31/485			
	NP	0	3	3	0	0	7	0	8/98	WO	A61K	31/485			
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)															
	NQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice." Brain Research (1997), 757:176-190.													
	NR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.													
EXAMINER /Humera Sheikh/											DATE CONSIDERED 08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CCN		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	OD 4 4 2 9 4 3	12/95	Crain et al.	514	10		
	OB 5 4 5 6 2 6 6	10/95	Portoghese et al.	546	35		
	OF 4 2 0 4 4 2	6/95	Zagon et al.	514	282		
	OD 5 3 2 6 6 6 2	12/94	Cockert	514	282		
	OD 5 3 5 6 0 0 0	10/94	Bihari et al.	514	282		
	OF 0 3 0 2 0 0 3	10/94	Mayer et al.	514	289		
	OG 5 3 5 2 6 6 6	10/94	Portoghese et al.	514	279		
	OH 5 3 2 4 0 4 2	5/94	Mayer et al.	514	25		
	OI 5 3 6 6 0 2 2	5/94	Borsodi et al.	514	282		
	OI 5 3 6 6 6 6 6	5/94	Rose et al.	424	10		
	OD 5 2 2 3 2 6 0	12/93	Oshlack et al.	424	486		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	OD 5 6 3 3 5 6 6	3/94	WO	A61K	9/20		
	OM 6 6 0 2 2 5 4	2/95	WO	A61K	31/485		
	CI 5 5 0 3 6 0 4	2/95	WO	A61K	31/485		
	OO 6 4 0 6 4 2 6	3/94	WO	A61K	31/46		
	OH 5 3 0 3 4 6 7	9/83	WO	A61K	9/22		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	OD	Mendelson J., et al., "Buprenorphine and Naloxone Interactions in Cypate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.					
	OF	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocaine, Hydromorphone and their Combination in Humans," (1996).					
EXAMINER			DATE CONSIDERED				
/Humera Sheikh/			08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	PH 8 2 5 8 8 5 5	10/93	Askanazi et al.	514	282		
	P9 5 2 3 5 7 4 4	8/93	Lee et al.	424	449		
	PE 5 2 2 5 4 4 5	7/93	London et al.	514	535		
	PO 5 4 5 5 5 5 8	9/92	Granger et al.	424	449		
	PE 5 7 5 2 5 5 7	9/92	Goldberg	514	282		
	P9 5 5 5 5 7 4 5	9/92	Sinclair	424	449		
	PG 6 5 5 6 5 5 5	2/92	Sinclair et al.	514	282		
	PH 8 3 8 8 8 8 7	12/91	Mendelson et al.	514	282		
	PE 4 5 3 5 4 2 8	8/95	Lewis	514	282		
	PE 8 8 8 9 8 8 0	12/91	Rzesutowski et al.	514	282		
	PH 8 8 8 8 8 8 8	10/93	Sinclair	514	282		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	PH						
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)							
	PM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.					
	PN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Colreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.					
	PO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.					
	PH	Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ, 2120-2121.					
	PO	Foss et al., J. Clin Pharmacol (1993), 33:747-751.					
EXAMINER			/Humera Sheikh/				
			DATE CONSIDERED 08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
						YES	NO
	QA	7 8 7 3 0 7 8	10/89	Fishman et al.	412	45	
	QB	8 8 8 1 7 8 1	8/89	Goldberg	514	282	
	QC	3 2 2 3 3 3 8	9/89	Oshlack et al.			
	QF	3 8 0 2 8 8 8	2/89	Wuest et al.	514	381	
	QF	3 2 2 2 0 3 0	2/89	Choi	514	464	
	QF	3 8 0 2 3 8 1	2/89	Chien et al.	424	448	
	QC	3 2 2 3 7 2 8	2/89	Pasternak	514	282	
	QI	8 7 8 0 0 0 0	10/89	Kreek et al.	514	282	
	QI	8 7 0 3 3 7 2	9/88	Kreek et al.	514	282	
	QI	7 7 0 0 0 0 0	7/88	Rzeszotarski et al.	514	282	
	QI	7 3 3 3 0 7 0	9/88	Portoghese et al.	546	45	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	QC						
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)							
	QM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.					
	QN	Mlaskowski et al., Brain Research (1992), 596:41-45.					
	QO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.					
	QP	Cappel et al., Pharma. Bioch. & Behav. (1999), 34:425-427.					
	QO	Vaccarino et al., Pain (1989), 36:103-109.					
	QR	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.					
EXAMINER			DATE CONSIDERED				
/Humera Sheikh/			08/01/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Oshlack, et al.		GROUP: 1615							
(Use several sheets if necessary)				FILING DATE: October 21, 2003									
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER	DATE							NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		RA	4	4	7	6	7	6					5
	RA	4	4	7	6	7	6	5	4/86	Goldberg	514	260	
	RE	4	6	6	4	4	6	4	8/84	Lewis et al.	514	282	
	RE	4	6	0	6	3	4	6	4/86	Pasternak	514	282	
	RD	4	6	4	4	6	4	5	4/86	Lewis et al.	514	260	
	RE	4	6	4	6	6	6	6	4/86	Chen et al.	514	260	
	RE	4	4	6	4	6	4	6	8/84	Hussain et al.	424	260	
	RG	4	4	6	4	6	6	4	8/84	Gordon et al.	424	260	
	RI	4	4	6	4	4	7	0	8/84	Ganti	424	260	
	RI	4	4	0	6	5	2	2	8/83	Portoghesi et al.	424	260	
	RJ	4	6	7	6	6	6	6	11/79	Goldberg	424	260	
	RI	6	6	6	6	6	4	0	6/76	Pachter et al.	424	260	
FOREIGN PATENT DOCUMENTS													
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
						YES	NO						
RI													
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)													
RM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.												
RD	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.												
RE													
RD													
RR													
EXAMINER				DATE CONSIDERED									
/Humera Sheikh/				08/01/2010									
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Oshlack, et al.		GROUP: 1615	
(Use several sheets if necessary)				FILING DATE: October 21, 2003			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	SB	3 2 7 0 5 5 0	4/75	Pachter et al.	424	260	
	SB	0 7 7 3 0 0 5	11/73	Pachter et al.	424	260	
	SG	3 0 7 0 0 0 4	7/72	Lachman et al.	424	260	
	SG	3 4 9 3 0 0 7	2/70	Lewenstein et al.	424	260	
	SE	3 3 3 2 0 0 0	7/67	Blumberg et al.	260	260	
	SI	2 7 7 0 0 0 0	11/56	Fromherz et al.	167	65	
	SG	0 0 0 4 0 7 0	12/99	O'Malley et al.	514	260	
	SI	0 4 2 0 0 0 0	9/00	Whilmire	424	497	
	SI	0 0 7 9 0 3 0	06/03	Hirsch et al.	424	497	
	SJ	0 0 0 0 0 7 0	06/03	Foss et al.	514	282	
	SK	0 0 0 0 4 4 9	04/04	Oshlack et al.	514	E02	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	SI						
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)							
	SM	Bentley, Function of Myocardial α -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112					
	SM	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
	SP	Yoburn, et al., Opioid Antagonist-Induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240					
	SP	Burzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ , δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
	SQ	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization. FEBS Letters 341 (1994) pg. 33-38					
	SR	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79					
	SS	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER				DATE CONSIDERED			
/Humera Sheikh/				08/01/2010			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CONSERIAL NO.:
10/689,866

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
October 21, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	TA	6	2	2	6	6	6	3	05/08/01	Palermo et al.	514	282	
	TQ	6	2	7	7	8	8	4	08/21/01	Kaiko et al.	424	400	
	TG	6	6	2	7	6	3	5	09/03	Palermo et al.	514	282	
	TQ	6	6	9	6	6	6	6	02/04	Kaiko et al.	424	490	
	TE	6	4	2	4	4	6	4	11/02	Kaiko et al.	424	490	
	TP	7	1	4	4	6	6	7	12/06	Oshlack et al.	424	490	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	TG	WO	98	2	6	6	4	3	06/18/98	EPO	A61K	31/485		X
	TH	WO	00	3	6	4	4	5	07/06/00	EPO	A61K	9/00		X

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

TI	Life Sci. 1982 31 pg 101-104
TJ	J Pharm. Exper. Ther. 1991 259(2) pg 582-589
TP	Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539
TL	J. Clin. Invest. 1988 82(5) pg 1574-1577
TM	Brain Res. 2001 888 pg 75-82
TN	Res. Comm. Sust. Abuse 1991 12(3) pg 119-131
TQ	Brain Res. Bull. 1994 33(2) pg 237-240
TP	FEBS Lett. 1994 347, pg 284-288
TQ	FEBS Lett. 1994 341 pg 33-38
TQ	FEBS Lett. 1994 348 pg 75-79
TS	Neuroscience 1998 82, pg 223-240
TT	J. Neuro Sci 1998 18, pg 9685-9694
TU	Neurosci. Lett. 1999 272, pg 183-186
TV	Eur. J. Pharmacol. 2000 404, pg 153-159

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

08/01/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.